Background: Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).
| INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in clinical practice, with an estimated 70% of cases classifiable as nonvalvular atrial fibrillation (NVAF). An estimated 33 million individuals are affected by AF worldwide, including 1%-4% of adults in Australia, Europe and the United States. 1 The incidence of stroke in patients with AF is nearly fivefold higher than that of the general population, resulting in significant morbidity and mortality. Also, AF-related strokes have higher mortality, greater disability, costs, and increased incidence of recurrent stroke compared with non-AF-related strokes. [2] [3] [4] For several decades, Vitamin K Antagonists (VKA, e.g. warfarin) were the primary oral anticoagulant used for stroke prevention in AF, being highly effective for preventing stroke and reducing all-cause mortality in patients with AF. However, managing the proper dose of warfarin to achieve the international normalisation range (INR) of 2-3 is difficult and lack of control is associated with a significant rate of major bleeding. 5 As a result, approximately 30%-50% of AF patients were undertreated with either suboptimal warfarin treatment, or given aspirin or no anticoagulation. 6 In recent years, four non-VKA oral anticoagulants (NOACs) have been approved for stroke prevention in AF. In clinical trials, all NOACs have all been shown to be at least as safe and effective as warfarin. 7 These new agents do not require regular INR monitoring and have few major drug and food interactions, as compared with warfarin. 7, 8 The four NOACs were approved States. Despite evidence on the efficacy and safety of these NOACs from randomised controlled trials, little is known about the bleeding events associated with the use of NOACs among NVAF patients in real-world settings. 9 The key objectives of this study were to (i) describe the clinical and demographic patient characteristics of newly anticoagulated NVAF patients who initiated apixaban, dabigatran, rivaroxaban, and warfarin in the United States; (ii) assess unadjusted rates of first major bleeding; and (iii) compare the risk of major bleeding among newly anticoagulated NVAF patients initiating apixaban vs warfarin, dabigatran or rivaroxaban, adjusting for demographic and clinical characteristics. Further, we also assessed the risk of major bleeding among newly anticoagulated NVAF patients initiating warfarin vs apixaban, dabigatran or rivaroxaban, adjusting for demographic and clinical characteristics.
| METHODS
A retrospective cohort study was conducted using Truven 
What's new
• Major bleeding risk was evaluated for oral anticoagulant initiators using US claims database.
• Rivaroxaban or warfarin had significantly higher major bleeding risk vs apixaban initiation.
• Only apixaban initiation had significantly lower major bleeding risk vs warfarin initiation.
• Dabigatran initiation had a non-significant major bleeding risk vs apixaban.
time prior to or on index date) were excluded. Patients with any evidence of pregnancy at any time during the baseline were excluded (Fig. 1 ).
A new initiator (i.e. new user) was required to have at least one claim with a diagnosis of AF and at least one prescription claim for oral anticoagulant (OAC), either warfarin, apixaban, dabigatran or rivaroxaban with no prior use of anticoagulant in the baseline. Index date was defined as the date of first prescription after the NVAF diagnosis. Index drug was defined as the first anticoagulation treatment prescribed to patients included in the study.
Major bleeding on an anticoagulant was defined as bleeding requiring hospitalisation (i.e. inpatient bleeding) any time during the period of drug use or within 30 days from the last day of supply of treatment prescription. Major bleeding was identified using hospital claims, which had a bleeding diagnosis code as the first listed ICD-9-CM diagnosis code. ICD-9-CM codes are provided in Table S1 . The definition of major bleeding was modified from a published administrative claims-based algorithm 10 and captures major bleeding at key sites, including but not limited to intracranial, gastrointestinal, liver, splenic and ocular haemorrhage requiring hospitalisation with a diagnosis for bleeding.
Patients were followed from the index date to the first major bleeding event, date of discontinuation from index medication, date of a switch, end of study period or interruption in continuous enrolment, whichever occurred earlier.
In the eligible population, baseline demographic and clinical categorical and continuous variables were compared across treatments using Pearson's chi-square test and Kruskal-Wallis test, respectively. Unadjusted rates of first major bleeding event were described as the number of bleeding events per 100 person-years and compared using Poisson distribution using both warfarin and apixaban as the reference category. To assess robustness of the main study results, we conducted the following sensitivity analysis:
• We defined first major bleeding on an anticoagulant as a major critical site bleeding in an inpatient or outpatient setting, occurring anytime during the period of drug use or within 30 days from the last day of supply of treatment prescription.
Major critical site bleeding was identified using inpatient as well as outpatient claims, which had a bleeding diagnosis code across primary and secondary ICD-9-CM diagnosis codes.
ICD-9-CM codes for major critical site bleeding are provided in Table S2 . This definition of major bleeding was assessed as a sensitivity analysis of the study for robustness of the main results.
• • Apixaban users have a shorter follow-up because apixaban was approved in the United States in December 2012. In order to account for the differences in follow-up, we censored patients at 90 and 180 days to create a more similar follow-up between the treatment cohorts. (Tables 1 and 2 ).
T A B L E 1 Baseline Demographic Characteristics by Index Anticoagulant Initiation

| RESULTS
The unadjusted incidence rate (per 100 person-years) for major bleeding requiring hospitalisation was 4.66 for warfarin, 4.57 for rivaroxaban, 3.38 for dabigatran and 2.35 for apixaban patients (Table S3 ).
The cumulative incidence of major bleeding for new initiations on anticoagulants is represented in Fig. 2 . Table 3 and Fig. 3 ). Besides OAC treatment, the factors associated with major bleeding requiring hospitalisation included the following: history of prior bleeding and comorbidities, including congestive heart failure, renal disease and dyspepsia or stomach discomfort (Table 3) .
T A B L E 2 Baseline comorbidities and co-medications by index anticoagulant initiation
| Major critical site bleeding in inpatient or outpatient setting
The unadjusted incidence rate (per 100 person-years) for major critical site bleeding in an inpatient or outpatient setting was 13.01 for warfarin compared with 8.15 for apixaban, 12.41 for rivaroxaban and 9.01 for dabigatran. These unadjusted incidence rates showed a similar pattern to the unadjusted incidence rates obtained for major bleeding requiring hospitalisation in the main analysis. had a numerically greater but non-significant risk of major bleeding compared with those initiated on apixaban ( (Tables S3, S4 and Figs S1, S2 ).
F I G U R E 2 Cumulative incidence of major bleeding requiring hospitalisation for anticoagulant initiation
| DISCUSSION
In this study, we show that among newly anticoagulated NVAF patients in the real-world US setting, initiation with rivaroxaban or warfarin was associated with a significantly greater risk of major bleeding as compared with initiation on apixaban. No prior observational study has evaluated risk of major bleeding as a comparative safety between various oral anticoagulants, apixaban and other NOACs or warfarin. The results of this study corroborates indirect treatment and network meta-analysis findings, based on clinical trials data, that apixaban was associated with a significantly lower hazard of major bleeding compared with warfarin and rivaroxaban. [14] [15] [16] Previous studies have presented the incidence and HRs of risk of major bleeding for rivaroxaban vs warfarin and dabigatran vs warfarin in real-world settings. The findings of this study are qualitatively comparable to other real-world studies focused on rivaroxaban vs warfarin 17 and dabigatran vs warfarin. 18, 19 This study used real-world claims data from the US population to demonstrate comparative safety in an adult NVAF population newly initiated on warfarin, rivaroxaban, dabigatran or apixaban therapy.
Apixaban has been available in the United States since 2013; thus, the follow-up period on apixaban was relatively shorter compared with warfarin, rivaroxaban and dabigatran in this study. Despite major bleeding being a relatively rare event, the risk differences between the treatments groups were detected and the study was focused on new- Besides OACs, factors associated with the risk of major bleeding requiring hospitalisation were a history of prior bleeding and comorbidities, including congestive heart failure, renal disease and dyspepsia or stomach discomfort. Besides OACs, factors associated with the risk of major critical site bleeding in an inpatient or outpatient setting, were history of prior bleeding, higher categories of CCI, and comorbidities, including congestive heart failure, dyspepsia or stomach discomfort, myocardial infarction, renal disease and male gender (as a protective factor). These risk factors associated with major bleeding were consistent with the findings from the ARISTOTLE trial, where older age, prior haemorrhage, prior stroke or TIA, diabetes, lower creatinine clearance and decreased haematocrit level were shown to be independently associated with an increased risk of major bleeding. 22 Furthermore, warfarin was preferentially initiated among older and sicker patients among newly anticoagulated NVAF patients. Among those initiating NOACs, however, apixaban patients were older and had a greater baseline clinical risk compared with those initiating dabigatran or rivaroxaban. Thus, randomised controlled trial findings are robust to variation in patient characteristics including age, baseline clinical risk and comorbid conditions.
T A B L E 3 Risk of major bleeding requiring hospitalization among patients initiating anticoagulants after adjusting for clinical and demographic characteristics
When assessed using the standard of care warfarin as a reference comparison, we observed that the real-world major bleeding results were in concordance with results observed in clinical trials. For patients newly initiated on dabigatran, as compared with warfarin, the risk of major bleeding was shown to be lowered by 12%-21%. 18, 23 These results are generally consistent with the lower risk of major bleeding for dabigatran compared with warfarin, as demonstrated in the RE-LY trial. 24 Patients newly initiating rivaroxaban, as compared with warfarin, were numerically more likely to experience a major bleeding event but the adjusted differences in major bleeding between rivaroxaban and warfarin did not reach statistical significance. This is consistent with numerically higher adjusted risk of major bleeding with rivaroxaban compared with warfarin as demonstrated in the ROCKET-AF trial.
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In the real-world studies conducted using the healthcare claims database, 17 a numerically higher but non-significant risk of major bleeding was observed for rivaroxaban as compared with warfarin which is consistent with our study. Interestingly, our study showed similar crude incidence rates of major bleeding among rivaroxaban and warfarin patients (around 4.6 per 100 person-years) although studies have
shown that the mean time in therapeutic range (TTR) is relatively low in real-world settings, usually below or around 60%. 26, 27 In addition, the incidence rate of major bleeding (per 100 person-years) was higher than previously reported in the XANTUS study (2.1; 95% CI: 1.8-2.5), Dresden NOAC registry (3.1; 95% CI: 2.2-4.3), and a retrospective claims study using the US Department of Defense health records (2.9; 95% CI: 2.61-3.13). [28] [29] [30] These differences in incidence rates may be because of the difference in study design, patient selection criteria, and the definition of major bleeding.
F I G U R E 3 Unadjusted incidence rates of major bleeding requiring hospitalisation (per 100 person-year) and adjusted hazard ratios for anticoagulant initiation -apixaban, rivaroxaban, and dabigatran compared with warfarin. Hazard ratios (HRs) are adjusted based on the Cox proportional hazards model adjusted for: age, sex, region, embolic or primary ischaemic stroke, dyspepsia or stomach discomfort, congestive heart failure, coronary artery disease, diabetes, hypertension, renal disease, myocardial infarction, history of stroke or transient ischaemic attack, history of bleeding, Charlson comorbidity Index score and baseline medications, including angiotensin converting enzyme inhibitor, amiodarone, angiotensin receptor blocker, beta blocker, H2-receptor antagonist, proton pump inhibitor and statins.
For patients newly initiated on apixaban, compared with warfarin, there was a statistically significant reduction by 38%-48% in the risk of major bleeding. These results are consistent with the statistically significant 31% relative reduction in the risk of major bleeding for apixaban compared with warfarin, as demonstrated in the ARISTOTLE trial. 31 Indeed, our study supports that the benefits of apixaban demonstrated in randomised clinical trial may also be achieved in a broad population receiving clinical care in routine practice.
A limitation of this study is that as with any retrospective observational study and common to database analysis, we can only study association between variables. As with any retrospective observational database study, there is a potential for selection bias. We It was also not possible to apply dose-adjustment in this analysis for following reasons: (i) Renal function and weights are not available in claims analyses and (ii) warfarin treatment is continuously dose-adjusted so there is no low-or high-dose strategy which can be defined in a manner similar to NOACs in the study.
Further, it is unclear if adjusted study results would be any different from a clinical study conducted with above variables in consideration.
The strengths of our study are that we assessed a real-world comparative safety of newly initiating warfarin, apixaban, rivaroxaban, and dabigatran using the comprehensive Truven MarketScan In conclusion, this study demonstrates that initiation with apixaban was associated with a significantly lower risk of major bleeding as compared with initiation on warfarin among newly anticoagulated NVAF patients in the real-world setting.
Furthermore, patients initiating on rivaroxaban or warfarin had a significantly greater risk of major bleeding compared with those initiating apixaban. There was no significant difference in the risk of major bleeding among patients newly initiated on dabigatran compared with apixaban or warfarin initiators. Future analyses using a large propensity matched cohort comparing the treatment effect on the risk of major bleeding is needed to confirm the current study findings.
